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Abstract
 
Rodents immunized with complete Freund’s adjuvant (CFA) are resistant to subsequent at-
tempts to induce autoimmune disease, while animals immunized with incomplete Freund’s ad-
juvant (IFA) remain susceptible. Mycobacterial extracts can stimulate inducible nitric oxide syn-
thase (NOS2) gene transcription. Robust expression of NOS2 has been linked to suppression of
T cell proliferation and alterations in immune responses. Our studies investigated the hypothesis
that the immunoprotective effect of CFA before immunization requires functional NOS2.
NOS2 gene expression is chronically elevated in lymph nodes and spleens of CFA-immunized
mice. Maximal expression of NOS2 after CFA immunization requires the presence of functional
type I tumor necrosis factor 
 

 
 receptor (TNFR1) and interferon 
 

 
. Groups of nontreated and
 
CFA-preimmunized male C57BL/6J or C57BL/6NOS2
 

 
/
 

 
 mice were immunized with mye-
lin oligodendrocyte glycoprotein (MOG) peptide 35–55 in CFA to induce experimental allergic
encephalomyelitis (EAE). Wild-type C57BL/6J mice were protected from the development of
symptoms of EAE, while the NOS2
 

 
/
 

 
 mice failed to be protected. NOS2-dependent effects of
CFA included an augmentation of the MOG-specific IgG1 response, a decrease in interleukin 6
production by MOG-reactive lymphocytes, and a marked decrease in mononuclear cell infil-
trates in the central nervous system. These studies support the hypothesis that CFA immuniza-
tion modulates immune responses through a nitric oxide–dependent mechanism.
Key words: experimental allergic encephalomyelitis • Freund’s adjuvant • immunosuppression • 
interleukin 6 • tumor necrosis factor 
 

 
Introduction
 
Exposure to CFA can impair the subsequent expression of
autoimmune disease in small rodents. This observation, also
referred to as “adjuvant immunotherapy,” was first de-
scribed over 40 years ago and found to be dependent on the
 
presence of 
 
Mycobacterium tuberculosis 
 
within the adjuvant (1).
This immunoprotective effect of CFA has been subse-
quently demonstrated in multiple autoimmune disease
models, both spontaneous and induced, and in multiple spe-
cies, including rats (2–5), mice (6), and guinea pigs (1, 7, 8).
In each case, preimmunization with CFA alone 21–40 d be-
fore attempted disease induction by immunization resulted
in a decreased incidence and severity of disease (1–3, 7, 8).
Much of our current understanding of the CFA effect is
derived from rodent models of spontaneous autoimmune
diabetes mellitus. A single injection of CFA into nonobese
diabetic (NOD)
 
1
 
 mice between the ages of 4 and 12 wk
prevents the development of clinical diabetes indefinitely
and extends NOD life span significantly (9–11). CFA im-
munization of recipient NOD mice blocks the ability of di-
abetogenic T cells to transfer disease (9). Treatment of
NOD mice with CFA at the time of islet cell transplanta-
tion blocks rejection and promotes the functional survival
of the graft (12, 13). CFA did not result in a generalized
state of immunosuppression, as evidenced by the ability of
the recipient to reject an allograft (12–14).
Cotransfer of diabetogenic T cell clones with splenocytes
from a CFA-treated mouse blocks the adoptive transfer of
disease (9). T cell or CD4
 

 
 cell depletion in the CFA-
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Abbreviations used in this paper:
 
 CNS, central nervous system; EAE, exper-
imental allergic encephalomyelitis; MOG, myelin oligodendrocyte glyco-
protein; NOD, nonobese diabetic.
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treated spleen eliminates the inhibitory effect (9). Enrich-
ment of the CFA treated splenocytes for Mac-1
 

 
 cells ab-
rogates the ability of splenocytes from a diabetic mouse to
cause disease in a prediabetic NOD mouse (15). These
findings may reflect a dual requirement for both T cells and
macrophages in mediating adjuvant immunotherapy. Con-
comitant treatment of BioBreeding rats with CFA and
anti–TNF-
 

 
 antibody eliminates the inhibitory effect of
CFA, suggesting that TNF-
 

 
 is a required mediator (16).
Nitric oxide (NO) generated through the cytokine-
inducible pathway has been increasingly recognized to play
an important role in immune regulation in models of au-
toimmune disease and T cell tolerance (17–21). Immune
responses induced with Ag in CFA are markedly aug-
mented in the presence of inducible NO synthase (NOS2)
inhibitors or when using NOS2
 

 
/
 

 
 mice. In this study, we
examined whether functional NOS2 was required for the
protective effect of CFA.
 
Materials and Methods
 
Experimental Animals.
 
Male C57BL/6, C57BL/6NOS2
 

 
/
 

 
,
C57BL/6IFN-
 

 

 
/
 

 
, and C57BL/6TNFR1
 

 
/
 

 
 mice were ob-
tained from The Jackson Laboratory. The mice were used be-
tween 4 and 6 wk of age. Mice were housed and handled in ac-
cordance with Veteran’s Affairs and National Institutes of Health
guidelines under Institutional Animal Care and Use Committee–
approved protocols.
 
Reagents.
 
Myelin oligodendrocyte glycoprotein (MOG) pep-
tide 35–55 N-MEVGWYRSPFSRVVHLYRNGK-C was pre-
pared by custom solid phase synthesis (Research Genetics). IFA
and 
 
Mycobacterium tuberculosis
 
 H37RA was obtained from Difco
Labs. Purified pertussis toxin was obtained from List Biochemicals.
 
CFA Pretreatment and Experimental Allergic Encephalomyelitis In-
duction.
 
Mice to be evaluated for CFA-mediated protection
were immunized i.p. 28 d before pMOG
 
35–55
 
 immunization with
100 
 

 
l of CFA (prepared as 0.5 mg/ml 
 
M. tuberculosis
 
 H37RA in a
1:1 (vol/vol) emulsion of Freund’s adjuvant and PBS). To induce
experimental allergic encephalomyelitis (EAE), mice were immu-
nized s.c. with 300 
 

 
g of pMOG
 
35–55
 
 and 400 
 

 
g of 
 
M. tuberculosis
 
H37RA in 200 
 

 
l of Freund’s adjuvant. Additionally, mice were
injected i.p. with 500 ng of pertussis toxin in 50 
 

 
l of PBS at the
time of pMOG
 
35–55
 
 immunization and 48 h later. Mice were eval-
uated daily for signs of disease. The clinical course of the EAE was
scored according to the severity as follows: 0 
 

 
 no obvious signs
of disease, 0.5 
 

 
 partial tail weakness, 1 
 

 
 limp tail, 1.5 
 

 
 limp
tail and hindlimb weakness, 2 
 

 
 limp tail and impairment in
righting reflex, 2.5 
 

 
 limp tail and hindlimb paresis, 3 
 

 
 bilateral
hindlimb paralysis, 3.5 
 

 
 bilateral hindlimb paralysis and forelimb
paresis, 4 
 

 
 moribund, and 5 
 

 
 dead. The mice were followed
for a total of 28 d, at which point the mice were killed. The brains
and spinal cords were prepared for histologic evaluation by careful
dissection and fixation in 10% neutral buffered formalin.
 
CFA Treatment to Induce NOS2 Expression.
 
Mice were im-
munized s.c. at the base of the tail with CFA. At the indicated
day (see Fig. 1 legend) after CFA immunization, the mice were
killed, and draining lymph nodes, spleen, liver, and kidney were
harvested. Of these tissues, half was flash frozen in liquid N
 
2
 
, and
total RNA was prepared from the remaining half.
 
Histology.
 
Paraffin blocks of the fixed spinal cords were pre-
pared. Transverse and longitudinal sections were cut and placed
on a frost-free glass slide. Sections were stained for myelin with
Luxol Fast Blue. The cellular infiltrate was evaluated by hema-
toxylin and eosin staining. Sections were scored according to the
following system: 0 
 

 
 no sign of infiltrate, 1 
 

 
 perivascular con-
gestion (light), 2 
 

 
 perivascular congestion (heavy), 3 
 

 
 perivas-
cular congestion (heavy) and parenchymal infiltrate, 4 
 

 
 focal
meningeal lymphocytosis, and 5 
 

 
 extensive sclerosis.
 
Proliferation Assays.
 
Spleens were harvested and prepared as
single-cell suspensions with a metal screen. RBCs were lysed by a
room temperature incubation in a hypotonic solution (0.83%
NH
 
4
 
Cl, 0.02 mM Tris, pH
 
 
 
7.6). Proliferation assays were set up
as described previously (22). Cells assayed for proliferation were
pulsed with 1 
 

 
Ci/well [
 
3
 
H]thymidine (Amersham Pharmacia
Biotech) at 48 h and harvested 18 h later.
Figure 1. CFA-immunized C57BL/6 mice have long-term augmented
basal NOS2 expression in lymphoid tissues. (A and B) C57BL/6J mice
(n  6) were immunized s.c. with 200 l of CFA. On the indicated days,
mice were killed and total RNA prepared from draining lymph nodes (A)
and spleen (B). Samples were evaluated for NOS2 and -actin mRNA
concentrations by competitive reverse transcription (RT)-PCR. (C) Se-
rum was isolated from the mice described above. Total nitrate and nitrite
was determined by complete Griess assay. Analysis of variance (ANOVA)
with Bonferroni/Dunn post-test: *P  	 0.003, **P  	 0.0002.
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Cytokine ELISAs.
 
Culture supernatant concentrations of IL-
4, IL-6, IFN-
 

 
, and TNF-
 

 
 were determined by sandwich
ELISA with antibodies purchased from PharMingen. IL-4, IL-6,
IFN-
 

 
, and TNF-
 

 
 concentrations were determined from cul-
ture supernatants after 66 h of activation with soluble MOG pep-
tide. Antibody dilutions that maximized signal to noise were de-
termined for each antibody pair, and ELISAs were performed as
described previously (22).
 
Serum MOG-specific Antibody Titer Determination.
 
 Serum was
collected from mice by terminal cardiac puncture. Samples of se-
rum were analyzed at various dilutions. Briefly, 96-well MAX-
ISORP™ microtiter plates (Nunc-Nalgene) were treated with
0.2% glutaraldehyde (Sigma-Aldrich) for 2 h at 37
 


 
C. Plates were
 
coated with pMOG
 
35–55
 
 (1 
 

 
g/ml in 0.1 M carbonate buffer, pH
9.6) for 3 h at 37
 


 
C and washed three times with TBS–0.1%
Tween-20 (TBST). Plates were blocked overnight at 4
 


 
C with
PBS containing 2% BSA (Sigma-Aldrich) and 0.05% Tween-20
and washed once with TBST. Plates were incubated with serum
samples for 1 h at 37
 


 
C and washed three times with TBST.
Plates were developed with anti-IgG (Calbiochem), anti-IgG
 
1
 
(Caltag Laboratories), or anti-IgG
 
2a
 
 (PharMingen) alkaline phos-
phatase conjugates at 37
 


 
C for 1 h and washed five times with
TBST. Color was developed by incubating plates with 
 
p
 
-nitro-
phenylphosphate disodium purchased from Sigma-Aldrich (1
mg/ml in 1 M carbonate buffer, pH 9.6) at room temperature for
equal amounts of time. Color development was evaluated in a
microplate reader at 605 nm.
 
Competitive Reverse Transcription PCR.
 
Total RNA was pre-
pared from draining lymph node, spleen, liver, and kidney with
the RNeasy Mini™ kit (QIAGEN) and stored at 
 

 
70
 


 
C with
40 U of RNase-OUT™ inhibitor purchased from GIBCO BRL.
cDNA was prepared from 2 
 

 
g of each sample using a kit from
GIBCO BRL (Superscript II preamp™) according to the manu-
facturer’s instructions. The cDNA was used in a PCR reaction
with serial dilutions of a known molar amount of a competitive
template for NOS2 (CLONTECH Laboratories, Inc.) and 
 

 
-actin
and performed as described previously (22).
Figure 2. CFA-augmented basal NOS2 expression in lymphoid tissues
is dependent on the expression of IFN- and TNFR1. (A and B) Wild-
type, C57BL/6IFN-/ (n  6), and C57BL/6TNRF1/ mice were
immunized s.c. with CFA. On day 28, mice were killed and total RNA
prepared from draining lymph nodes (A) and spleen (B). Samples were
evaluated for NOS2 and -actin mRNA concentrations by competitive
RT-PCR. ANOVA with Bonferroni/Dunn post-test: *P  0.0001. Open
bars, wild-type mice; hatched bars, IFN-/ mice; black bars, TNFR1/
mice. (C) Serum was isolated from the mice described above. Total nitrate
and nitrites were determined by complete Griess assay. ANOVA with
Bonferroni/Dunn post-test: #P  0.001, †P  0.0001, ††P  0.002.
Figure 3. CFA protection of C57BL/6J mice from pMOG35–55-
induced EAE requires NOS2 expression. (A) C57BL/6J mice (n  15)
were immunized i.p. with 100 l of CFA containing 50 g of M. tubercu-
losis H37Ra. On day 28, these mice, along with a group of nonimmu-
nized C57BL/6J mice (n  15), were immunized s.c. with 300 g of
pMOG35–55 to induce EAE. Mice were scored daily for signs of clinical
disease. Day numbering in the figure corresponds to days after MOG/
CFA immunization. (B) C57BL/6NOS2/ mice (n  15) were pre-
treated with CFA as above. On day 28, these mice, along with a group of
nonimmunized C57BL/6NOS2/ mice (n  15), were immunized s.c.
with 300 g of pMOG35–55 to induce EAE. Mice were scored daily for
signs of clinical disease.
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Statistics. Differences were statistically analyzed using un-
paired Student’s t test. Analysis was accomplished with STAT-
VIEW™ (v4.5; Abacus Concepts).
Results and Discussion
CFA Immunization Induces Chronic NOS2 Expression in
Lymphoid Tissues. Immune responses induced by immu-
nizations with Ag in CFA are augmented in the absence of
functional NOS2 (20–22). We examined whether NOS2
expression is induced in lymphoid tissue after immuniza-
tion with CFA alone. Fig. 1 A and B depict a time course
of NOS2 mRNA expression levels in draining lymph
nodes and spleen after a single CFA immunization. Levels
are increased by 28 d after immunization. Curiously, this
increase in NOS2 mRNA expression is maintained for up
to 14 mo after immunization. The kinetics of expression
appear to be similar in lymph node and spleen. Absolute
levels are higher in draining lymph node, and the increase
in NOS2 mRNA levels occurs slightly earlier in the spleen.
The relative levels of NOS2 mRNA in spleen and lymph
node depend on the site of CFA immunization: intraperi-
toneal injections result in heightened splenic mRNA ex-
pression relative to lymph node expression (data not
shown). Sera from CFA-immunized mice display aug-
mented levels of NOx (sum of nitrite and nitrate measured
by Griess reaction) starting 1 wk after immunization. The
dissociation between NOS2 mRNA and serum NOx at
438 d is unexplained but may reflect altered clearance of
NOx. Thus, a single immunization with CFA induces
chronic NOS2 expression in lymphoid organs. IFA immu-
nization does not elicit an increase in serum NOx or
NOS2 mRNA expression (data not shown).
CFA-induced NOS2 Expression Is Partially Dependent on
the Production of IFN- and the Expression of TNFR1. The
NOS2 gene is transcriptionally activated by proinflamma-
tory cytokines (23). We investigated whether IFN- and
TNF- were required for CFA induction of NOS2 by
immunizing C57BL/6, C57BL/6IFN-/, and C57BL/
6TNFR1/ mice with CFA and evaluating them 28 d later
for NOS2 mRNA expression in lymph node and spleen.
We used TNFR1/ mice rather than TNF-/ mice be-
cause TNFR1 is the primary mediator of TNF-–depen-
dent nuclear factor (NF)-B activation, and TNF-/
mice have abnormal lymphoid organization (24, 25). As
shown in Fig. 2, the NOS2 mRNA levels in lymph nodes of
CFA-treated animals are significantly lower in both targeted
mutant strains. Serum NOx concentrations are significantly
lower as well. IFN-–deficient mice make only a partial re-
sponse, while those mice lacking TNFR1 have undetectable
levels of NOS2 mRNA in the lymph node and spleen. Sim-
ilar to observations made in wild-type mice, CFA-induced
NOS2 mRNA expression in IFN-–deficient mice was
greater in the lymph node than in the spleen. While the dif-
ference between CFA-induced splenic NOS2 mRNA ex-
pression in wild-type and mutant mice failed to reach statis-
tical significance, the pattern of hypoexpression is preserved
(Fig. 2 B). The serum NOx levels in the CFA-immunized
Figure 4. NO-dependent CFA-induced al-
terations of immune response to pMOG35–55.
Sera from C57BL/6 (n  12) and C57BL/
6NOS2/ (n  12) mice pretreated as indi-
cated were collected on day 10 after immuni-
zation with pMOG35–55. Sera were evaluated
by ELISA for titers of pMOG35–55-specific im-
munoglobulins. The OD values shown here
are from a serum dilution determined to be on
the linear part of the OD vs. dilution curve. A
depicts total IgG, and B depicts IgG1 and
IgG2a. The same dilution was used for all sam-
ples. Statistics determined from two-tailed un-
paired Student’s t test: in A, *P  0.0193, **P 
0.3085. In B, *P  0.0573, **P  0.3990,
†P  0.0521, ††P  0.0277. (C) CFA-induced
alterations in splenocyte cellular proliferation.
Splenocytes were taken from the mice de-
scribed in Fig. 5 on day 10. Cellular prolifera-
tion assay was performed at 2  106 cells/ml
to 50 g/well pMOG35–55. Cultures were
pulsed with 1 Ci/well [3H]TdR at 48 h and
incorporation assayed at 64 h. Statistical differ-
ences determined by two-tailed unpaired Stu-
dent’s t test. In C, *P  0.0583, **P  0.6361.
(D) NO-dependent CFA-induced alterations
of splenic cytokine production. Cytokine con-
centrations were determined by ELISA on the
supernatants from the splenic cultures in C.
Hatched bars, IL-4; gray bars, IFN-; open
bars, TNF-; black bars, IL-6. Statistical dif-
ferences determined by unpaired Student’s t
test. In D, *P  0.0025, **P  0.2677.
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TNFR1/ mice are elevated compared with unimmunized
controls, although not to the extent seen in the wild type.
Thus, both IFN- and TNFR1 are required for full induc-
tion of NOS2 in response to CFA.
Pretreatment of C57BL/6 Wild-Type but Not NOS2/
Mice with CFA Results in Protection from MOG-induced
EAE. To examine whether CFA induction of NOS2
might account for the ability of CFA to modulate disease
expression, we used the murine model of EAE induced by
immunization with an encephalitogenic MOG peptide in
CFA (18). Mice immunized with pMOG35–55 develop a se-
vere, chronic, nonremitting form of EAE. This illness de-
velops over 20–30 d as shown in Fig. 3 A. Consistent with
previous reports in other model systems, C57BL/6 mice are
protected from the development of MOG-induced EAE by
a single injection of CFA i.p. 28 d before immunization
with MOG/CFA. Of the 15 wild-type mice immunized
with MOG/CFA 28 d after i.p. CFA, only 5 had any de-
tectable clinical evidence of disease, and only 1 animal de-
veloped symptoms more severe than a symptom score of 2.
In contemporaneous experiments, we examined the ef-
fect of CFA preimmunization on the course of EAE in
MOG/CFA-immunized C57BL/6NOS2/ mice. The
disease course in these mutant mice is depicted in Fig. 3 B
and confirms previous reports that this disease is more se-
vere in the NOS2/ mice. By day 27 after MOG/CFA
immunization, the mean clinical scores are above 4.0 in the
NOS2/ mice, compared with 2.5 in the C57BL/6
wild-type mice. NOS2/ mice preimmunized with CFA
all develop significant clinical disease by day 27. Between
days 17 and 21 after MOG/CFA immunization, the disease
course appears to transiently stabilize in the CFA-preim-
munized animals before accelerating to fulminant disease.
Therefore, while CFA preimmunization may transiently al-
ter the course of disease in the NOS2/ mice, it does not
impart the same level of protection seen in the C57BL/6
wild-type mice.
NO-dependent CFA Immunomodulation Alters the Humoral
Response after Immunization with MOG. In a second series
of experiments, we examined whether preimmunization
with CFA altered the subsequent immune response to
MOG/CFA in both wild-type and NOS2/ mice. Both
strains were preimmunized with CFA and then 28 d later
immunized with MOG/CFA as for disease induction. On
day 10 after MOG/CFA immunization, the mice were
killed. Sera from experimental groups were evaluated for
anti-MOG total IgG, IgG1, and IgG2a antibody titers.
Spleens from all animals were assayed for their proliferative
responses and cytokine production in response to MOG.
As shown in Fig. 4 A, wild-type mice pretreated with
CFA have significantly augmented levels of anti-MOG IgG
compared with wild-type mice not preimmunized with
CFA. Under the conditions of this assay, we do not detect
anti-MOG IgG in the serum of naive mice (data not
shown). The total anti-MOG IgG levels in NOS2/ mice
are not augmented with CFA pretreatment and are compa-
rable to the wild-type mice immunized with MOG/CFA.
The increase in total anti-MOG IgG in CFA-pretreated
wild-type mice is mainly due to a substantial increase in
anti-MOG IgG1 concentrations. Again, this does not occur
in NOS2/ mice (Fig. 4 B). The increases in MOG-spe-
cific IgG2a in both strains pretreated with CFA are small
but statistically significant.
Splenocytes from the groups described above were as-
sayed in vitro for proliferative responses to pMOG35–55.
Consistent with a regulatory role for NO on T cell prolif-
eration, NOS2/ mice display greatly augmented prolifer-
ative responses to MOG compared with wild-type mice
(Fig. 4 C). CFA pretreatment failed to significantly alter
these proliferative responses in either strain. Fig. 4 D dem-
onstrates the cytokine profiles produced in response to
MOG from the various experimental groups. A screen of
Figure 5. NO-dependent CFA-induced prevention of CNS infiltrate.
Spinal cord tissue was harvested from the mice described in Fig. 4. Spinal
cord tissue from a wild-type (A) or NOS2/ mouse (B) preimmunized
with CFA before MOG/CFA challenge. Panel C depicts disease scores
from all of the animals studied in these groups. *P  0.01, **P  0.1.
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cytokines critical for either the development of EAE or of
NOS2 regulation showed that pretreatment with CFA had
no statistically significant effect on the production of IL-4,
TNF-, or IFN-. However, IL-6 production was re-
duced by pretreatment with CFA in an NO-dependent
manner (Fig. 4 D).
CFA Pretreatment Causes an NO-dependent Reduction in
Early Histologic Evidence of Inflammatory Central Nervous
System Infiltrate after Immunization with MOG. CFA-pre-
treated and nonpretreated mice were evaluated on day 10
after pMOG35–55 immunization for early histologic changes
in the central nervous system (CNS). As shown in Fig. 5 A,
wild-type mice pretreated with CFA lack the extensive in-
filtrate seen in CNS tissue from mice with active EAE.
While CFA-pretreated wild-type mice have only minimal
evidence of infiltrate, healthy NOS2/ mice pretreated
with CFA clearly show histologic changes associated with
the development of EAE (Fig. 5 B). Scoring of the histol-
ogy from the various groups additionally demonstrates
CFA-mediated protection from early histologic disease in
wild-type mice that is not observed in the absence of
NOS2 (Fig. 5 C).
These studies support the hypothesis that the protective
effects of CFA preimmunization require functional NOS2.
CFA-preimmunized NOS2 knockout mice fail to be pro-
tected from the development of EAE. Wild-type mice
protected by CFA demonstrate several alterations in their
immune response to MOG that may be relevant to the
mechanism of protection. The augmentation of anti-
MOG IgG1 titers is likely an epiphenomenon rather than
responsible for disease protection, as antibodies are not ma-
jor effector mechanisms of disease in the MOG peptide
model of EAE (26). It is interesting that NOD mice
treated with CFA demonstrate an augmented IgG1 re-
sponse to GAD67, consistent with our observation (27).
The NO-dependent inhibition of IL-6 production with
CFA treatment is highly significant. IL-6–deficient mice
are entirely resistant to MOG-induced EAE (28–30). Fur-
thermore, the mice that have been genetically modified to
overexpress IL-6 in the CNS develop EAE spontaneously
(31). The mechanism by which NO inhibits the expression
of IL-6 may well be due to inhibition of NF-B activa-
tion, which has been previously attributed to NO-depen-
dent stabilization of IB (32). We cannot rule out effects
of NOS2-generated NO on adhesion molecule expression
and egress of effector T cells from the vasculature into the
CNS (33). Our results are consistent with previous studies
in models of autoimmune diabetes that demonstrate im-
portant protective effects of TNF- (16). These studies
provide further support for the importance of NOS2 in
immunoregulation and suggest that chronic stimulation of
NOS2 in vivo may have profound effects on subsequent
immune responses. Given the continued interest in bacillus
Calmette-Guerin vaccines for individuals predisposed to
autoimmune diseases such as type I diabetes mellitus, de-
lineation of the mechanism of the CFA effect remains an
important goal.
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